Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.SSE: 688336

Report for Q1 2026

Apr 25, 2026 · Issued by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Apr 25, 2026

On 6ix: 6ix.com/news/report-for-q1-2026-565

Report for Q1 2026

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. on 6ix

Earlier from Sunshine Guojian Pharmaceutical (Shanghai)

Announcement on Expanding Business Scope and Amending "Articles of Association"Apr 15
Announcement on Changing Audit Institution for 2026Apr 11
Announcement on Resolutions of the 14th Meeting of the 5th Board of DirectorsMar 31
Announcement on Equity Change of Shareholders Reaching 1% Scale and Results of Shareholding ReductionFeb 28
Announcement on Voluntary Disclosure of New Drug Application Acceptance for the Recombinant Anti-IL-4Rα Humanized Monoclonal Antibody InjectionFeb 26

Later from Sunshine Guojian Pharmaceutical (Shanghai)

Announcement on Serious Abnormal Fluctuations in Stock TradingMay 20
Announcement on Implementation of Dividend Distribution for 2025Jun 12
Announcement on Abnormal Fluctuations in Stock TradingJul 2
Announcement on the Listing and Trading of the Shares Vested during the First Vesting Period of the Initial Grant under the 2024 Restricted Stock Incentive PlanJul 8
Sunshine Guojian Releases 2026 Interim Report:Aug 21

All Sunshine Guojian Pharmaceutical (Shanghai) news releases

Follow Sunshine Guojian Pharmaceutical (Shanghai) into a list and get an email when it puts out news.

Follow Sunshine Guojian Pharmaceutical (Shanghai)